C.R. Bard, Inc. (Bard) has reported net sales of $624.6 million for the second quarter of 2009, up 1%, compared with the net sales of $617.1 million in the year ago quarter. It also reported a net income attributable to common shareholders of $112.2 million, or $1.11 per diluted share, for the second quarter of 2009, compared with the net income attributable to common shareholders of $77.9 million, or $0.76 per diluted share, in the year ago quarter.
For the second quarter 2009, net sales in the US were $433.6 million and net sales outside the US were $191.0 million, an increase of 7% and a decrease of 9%, respectively, over the prior-year period. Excluding the impact of foreign exchange, second quarter 2009 net sales outside the US increased 5% over the prior-year period.
Timothy M. Ring, chairman and chief executive officer, commented, “We delivered another quarter of solid adjusted EPS growth despite continuing macroeconomic challenges. We are carefully managing our discretionary expenses while continuing to invest in R&D and business development to support our growth objectives. We believe that product leadership is the key to growth in our markets, and our commitment to this strategy remains unchanged.”
Bard is a company engaged in the design, manufacture, packaging, distribution and sale of medical devices.